An observational study in Acute Cerebrovascular Accident, Large Vessel Occlusion and Endovascular Thrombectomy, sponsored by Kuang Tien General Hospital. Completed at 1 site in Taiwan. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-06.
Sponsored by Kuang Tien General Hospital · Observational
This study will examine how well two existing prediction tools, THRIVE and CLEOS, predict recovery after a stroke caused by a blockage in a large blood vessel in the brain. It will review the medical records of adults who underwent endovascular thrombectomy, a procedure that removes the blood clot, at Kuang Tien General Hospital in Taiwan.
THRIVE uses age, stroke severity, and certain existing medical conditions. CLEOS uses age, stroke severity, blood glucose, and information from brain imaging. The study will compare how accurately these tools predict disability and death 90 days after stroke, including recovery among patients whose blocked blood vessels were successfully reopened.
The findings may help clinicians discuss expected recovery with patients and families and plan care after stroke. This observational study does not assign treatments or change patients' medical care.
Clinical outcomes after endovascular thrombectomy (EVT) for acute ischemic stroke vary despite successful reperfusion. This study evaluates the transportability of two established pretreatment prognostic scores to Taiwanese routine-care patients. Prognostic performance in treated patients does not estimate treatment benefit and must not be used alone to withhold EVT.
THRIVE denotes Totaled Health Risks in Vascular Events and includes age, presenting National Institutes of Health Stroke Scale (NIHSS), hypertension, diabetes mellitus, and atrial fibrillation. CLEOS denotes Charlotte Large Artery Occlusion Endovascular Therapy Outcome Score and includes age, NIHSS, initial glucose, and CT-perfusion cerebral blood volume index (CBVI) [1-3]. The different CLEOS expansion and citation in the source manuscript are corrected here.
Objectives Primary objective: compare THRIVE and CLEOS discrimination for 90-day poor functional outcome (modified Rankin Scale [mRS] 3-6) in the same patients with both scores and an observed outcome. Primary performance contrast: AUC(CLEOS) minus AUC(THRIVE), with a 95% confidence interval and paired DeLong test.
Secondary objectives: assess mortality, the full ordinal mRS distribution, original-endpoint severe disability/death (mRS 4-6), and futile recanalization among patients with successful reperfusion. Assess calibration only when a valid, frozen original probability equation for the endpoint is available; otherwise evaluate score discrimination and clearly identified locally fitted models.
8,255 studies on the registry are indexed under Stroke; 2,056 are open to participants now.
This study's enrollment of 233 is above the median of 152 across 1,968 observational studies indexed under Stroke.
Browse Stroke studies →Kuang Tien General Hospital is the lead sponsor of 11 studies on the registry; 2 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Identify consecutive adults receiving EVT for acute ischemic stroke at Kuang Tien General Hospital within the approved cohort interval using the stroke registry, procedure logs, electronic medical records, and imaging archive. Cross-check ascertainment across sources. Use one index EVT-treated stroke per participant: the first eligible event during the interval. Record repeat procedures within the same episode without double-counting participants.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
mRS
Proposed final-analysis rule: use the observed mRS nearest day 90 within days 76-104, breaking equal-distance ties using the later assessment. Investigators must approve this window and audit historical assessments before applying it. A confirmed death on or before day 90 is mRS 6 regardless of missing functional follow-up. An assessment after day 90 must not retrospectively classify death after day 90 as day-90 mortality.
Time frame: 90 days after endovascular thrombectomy
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Kuang Tien General Hospital